Full-Time

LIMS Systems Manager

Posted on 8/15/2025

Deadline 9/30/25
Synlab

Synlab

5,001-10,000 employees

Medical diagnostic laboratory services provider

No salary listed

United Kingdom

In Person

Category
Medical, Clinical & Veterinary (1)
Requirements
  • Knowledge of a range of IM&T areas, acquired through a degree or equivalent qualification/experience.
  • Knowledge of Caldicott Procedures and awareness of the Data Protection Act.
  • High level of computer literacy and knowledge.
  • Good degree of accuracy and numeracy.
  • Ability to communicate with a wide range of staff at all levels.
  • Excellent interpersonal and team-working abilities.
  • Strong personal time management skills.
  • Ability to adapt efficiently to change and plan activities within your area of work.
  • High degree of dexterity and the ability to concentrate for prolonged periods.
Responsibilities
  • Act as the Subject Matter Expert for pathology IT systems, gaining a detailed understanding of their operational and reporting capabilities.
  • Serve as the System Administrator for the LIMS, providing support, training, and issuing user credentials to staff.
  • Troubleshoot IT system problems on a day-to-day basis, report incidents to senior staff, and conduct root cause analysis.
  • Lead system updates and maintenance, including test sign-off, and provide expertise for future IT developments such as new interfaces and middleware enhancements.
  • Produce and manage standard operating procedures (SOPs) and other documentation using the Q-Pulse quality management system.
  • Plan and conduct audits to fulfill UKAS requirements, extract data to monitor KPIs, and work alongside Clinical Departmental Leads to align IT systems with clinical requirements.
  • Provide professional leadership and mentorship to staff, encouraging continuous professional development.
  • Lead the Change Advisory Board (CAB) for all pathology IT systems.
  • Report notifiable disease data to national governing bodies like SGSS.
Desired Qualifications
  • Expert knowledge of computer applications used in Pathology, including LIMS, Quality Management Systems, and interface systems.
  • IT Support or helpdesk experience.
  • Experience working in a biomedical laboratory.

SYNLAB provides a full range of medical laboratory services for practicing doctors, clinics, and patients. Its diagnostic tests cover human medicine and are processed through a wide network of labs across 36 countries and four continents, making it a leading partner for laboratory diagnostics in Europe. Tests are performed in certified laboratories using standardized procedures to deliver fast, reliable, high-quality results that doctors use to diagnose and monitor conditions. SYNLAB differentiates itself through its large European footprint, integrated laboratory network, and scale, which enable consistent, timely diagnostics across many sites. The company’s goal is to support better patient care by expanding access to accurate and efficient laboratory testing.

Company Size

5,001-10,000

Company Stage

Acquired

Total Funding

$1.7B

Headquarters

Munich, Germany

Founded

1998

Simplify Jobs

Simplify's Take

What believers are saying

  • Region Stockholm awarded 5-year contract starting April 2027 for diagnostics.
  • Labcorp acquired minority stake in 2024, enabling specialty test collaborations.
  • Cinven acquired Elliott's 10% stake in October 2024, consolidating control.

What critics are saying

  • Eurofins acquired Synlab Spain, eroding Iberian revenue immediately.
  • Medicover acquires Romanian labs, stripping Eastern European assets now.
  • Synnovis ransomware hack in June 2024 damaged UK trust and capacity.

What makes Synlab unique

  • SYNLAB leads European medical diagnostics with 500 labs across 36 countries.
  • Offers 5,000+ tests including clinical chemistry, microbiology, and pathology.
  • Operates 1,800+ blood collection points for accessible patient services.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Wellness Program

Professional Development Budget

Growth & Insights and Company News

Headcount

6 month growth

-3%

1 year growth

0%

2 year growth

1%
PharmiWeb.com
Mar 25th, 2025
Cinven Sells SYNLAB Stake to Labcorp

Cinven has completed the sale of an indirect minority stake in SYNLAB to Labcorp, a global leader in laboratory services. SYNLAB, a major player in medical diagnostics in Europe, achieved revenues of €2.62 billion in 2024. The companies plan to explore opportunities for Labcorp's specialty tests in Europe and potential collaborations. Labcorp, with nearly 70,000 employees, supported over 75% of new FDA-approved drugs in 2024.

Iberian Lawyer
Nov 5th, 2024
GA_P advises Synlab Group in the sale of Synlab España to Eurofins - Iberian Lawyer

Gómez-Acebo & Pombo has advised the Synlab Group, a leader in medical diagnostic services and specialized tests in Europe, in the sale of Synlab Spain to Eurofins Scientific (EUFI.PA).

PEI Group
Oct 30th, 2024
Cinven agrees to sell minority stake in Synlab | PE Hub

Synlab is a medical diagnostic services and specialty testing provider.

PharmiWeb.com
Oct 30th, 2024
Cinven To Acquire Elliott’S Stake In Synlab Ag, Squeeze-Out To Follow

EQS-News: SYNLAB AG / Key word(s): Miscellaneous/Squeeze OutCinven to Acquire Elliott’s Stake in SYNLAB AG, Squeeze-Out to Follow30.10.2024 / 07:32 CET/CESTThe issuer is solely responsible for the content of this announcement.Cinven to Acquire Elliott’s Stake in SYNLAB AG, Squeeze-Out to Follow Elliott to remain indirect minority shareholder in SYNLAB The Management Board of SYNLAB AG (“SYNLAB”) has been informed that international private equity firm Cinven has reached an agreement with funds advised by Elliott Advisors (UK) Limited (“Elliott”). Under this agreement, Cinven will acquire Elliott’s current direct minority stake of approximately 10% in SYNLAB. Elliott will become an indirect minority shareholder in SYNLAB, alongside existing shareholders Cinven, Labcorp (subject to regulatory approval), and Qatar Holding LLC. The transaction is subject to regulatory approvals and is expected to close in early 2025. The acquiring entity of Elliott’s shareholding will be Ephios Bidco GmbH (“Ephios Bidco”), an entity controlled by funds managed and/or advised by Cinven and the majority shareholder of SYNLAB AG. Ephios Bidco currently holds approximately 86% of the SYNLAB share capital

SYNLAB
Oct 28th, 2024
SYNLAB agrees to sell its Spanish business to Eurofins

SYNLAB agrees to sell its Spanish business to Eurofins.

INACTIVE